Prince Edward Island
TAKHZYRO is available in Prince Edward Island through the PEI Pharmacare Formulary (High Cost Drug Program, Catastrophic Drug Program)
Eligibility
For TAKHZYRO to be eligible for coverage by the PEI Pharmacare Formulary, prescribers must submit a limited use benefit request form and approval must be in place before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.
Reimbursement Criteria
We are pleased to inform you that TAKHZYRO (lanadelumab injection) is reimbursed in Prince Edward Island for your hereditary angioedema (HAE) patients who meet the following criteria:
For the prevention of attacks of HAE Type I or II in patients 12 years of age and older who have experienced at least three HAE attacks within any four-week period and required the use of an acute injectable treatment.
Discontinuation criteria
- No reduction in the number of HAE attacks for which acute injectable treatment was received during the first three months of treatment with lanadelumab compared to the number of attacks observed before initiating treatment with lanadelumab; or
- Increase in the number of HAE attacks for which acute injectable treatment was received compared to the number of attacks before initiating treatment with lanadelumab.
Clinical note
- The pre‐treatment attack rate must be provided for those patients who are already receiving long‐term prophylactic treatment for HAE and intend to transition to lanadelumab.
Claim notes
- The patient must be under the care of a physician experienced in the diagnosis and treatment of HAE.
- Not to be used in combination with other long‐term prophylactic treatment of HAE (e.g., C1 esterase inhibitor).
- Approvals will be for a maximum of 300 mg every two weeks.
- Initial approval period: 3 months.
- Renewal approval period: 6 months.
